$147 Million is the total value of BLUE JAY CAPITAL MANAGEMENT, LLC's 20 reported holdings in Q2 2017. The portfolio turnover from Q1 2017 to Q2 2017 was 90.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TSRO | Sell | TESARO INC | $9,439,000 | -27.5% | 67,490 | -20.3% | 6.43% | +0.5% |
| CLVS | Sell | CLOVIS ONCOLOGY INC | $9,279,000 | -2.8% | 99,101 | -33.9% | 6.32% | +34.7% |
| INCY | Buy | INCYTE CORP | $9,072,000 | -2.6% | 72,051 | +3.4% | 6.18% | +35.0% |
| IRWD | Sell | IRONWOOD PHARMACEUTICALS INC | $8,874,000 | -22.9% | 470,000 | -30.4% | 6.05% | +6.8% |
| WMGI | Buy | WRIGHT MED GROUP N V | $8,808,000 | -7.6% | 320,420 | +4.7% | 6.00% | +28.1% |
| BMRN | Sell | BIOMARIN PHARMACEUTICAL INC | $8,578,000 | -6.9% | 94,454 | -10.0% | 5.84% | +29.0% |
| PRAH | Sell | PRA HEALTH SCIENCES INC | $7,993,000 | -12.5% | 106,555 | -23.9% | 5.45% | +21.3% |
| EW | Sell | EDWARDS LIFESCIENCES CORP | $7,954,000 | -6.0% | 67,266 | -25.3% | 5.42% | +30.2% |
| ABMD | Sell | ABIOMED INC | $7,937,000 | -15.5% | 55,387 | -26.2% | 5.41% | +17.2% |
| NVRO | Buy | NEVRO CORP | $7,815,000 | -16.6% | 105,000 | +5.0% | 5.32% | +15.6% |
| QGEN | New | QIAGEN NV | $7,308,000 | – | 217,954 | +100.0% | 4.98% | – |
| SNN | New | SMITH & NEPHEW PLC | $6,970,000 | – | 200,000 | +100.0% | 4.75% | – |
| PTLA | New | PORTOLA PHARMACEUTICALS | $6,740,000 | – | 120,000 | +100.0% | 4.59% | – |
| NBIX | New | NEUROCRINE BIOSCIENCES INC | $6,684,000 | – | 145,303 | +100.0% | 4.55% | – |
| BKD | New | BROOKDALE SENIOR LIVING INC | $6,620,000 | – | 450,000 | +100.0% | 4.51% | – |
| ICLR | New | ICON PLC ORD | $6,194,000 | – | 63,342 | +100.0% | 4.22% | – |
| VRTX | Sell | VERTEX PHARMACEUTICALS INC | $5,954,000 | -32.1% | 46,202 | -42.4% | 4.06% | -5.9% |
| ALGN | New | ALIGN TECHNOLOGY INC | $5,090,000 | – | 33,904 | +100.0% | 3.47% | – |
| ILMN | New | ILLUMINA INC | $4,772,000 | – | 27,500 | +100.0% | 3.25% | – |
| ISRG | New | INTUITIVE SURGICAL INC | $4,677,000 | – | 5,000 | +100.0% | 3.19% | – |
| DERM | Exit | DERMIRA INC | $0 | – | -210,000 | -100.0% | -3.52% | – |
| AKRXQ | Exit | AKORN INC | $0 | – | -300,000 | -100.0% | -3.55% | – |
| MDRX | Exit | ALLSCRIPTS HEALTHCARE SOLUTN | $0 | – | -590,000 | -100.0% | -3.68% | – |
| CELG | Exit | CELGENE CORP | $0 | – | -72,902 | -100.0% | -4.46% | – |
| NUVA | Exit | NUVASIVE INC | $0 | – | -123,317 | -100.0% | -4.53% | – |
| BCR | Exit | BARD C R INC | $0 | – | -37,419 | -100.0% | -4.57% | – |
| BMY | Exit | BRISTOL MYERS SQUIBB CO | $0 | – | -200,000 | -100.0% | -5.35% | – |
| QGEN | Exit | QIAGEN NV | $0 | – | -390,000 | -100.0% | -5.55% | – |
| GMED | Exit | GLOBUS MED INC | $0 | – | -400,000 | -100.0% | -5.82% | – |
| BIIB | Exit | BIOGEN INC | $0 | – | -46,320 | -100.0% | -6.23% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-08-11
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC | 8 | Q2 2017 | 7.8% |
| EDWARDS LIFESCIENCES CORP | 8 | Q2 2017 | 8.4% |
| VERTEX PHARMACEUTICALS INC | 8 | Q2 2017 | 7.1% |
| SHIRE PLC | 7 | Q4 2016 | 6.4% |
| QIAGEN NV | 7 | Q1 2017 | 7.4% |
| BIOGEN INC | 6 | Q1 2017 | 7.0% |
| COOPER COS INC | 6 | Q1 2016 | 9.1% |
| INCYTE CORP | 6 | Q2 2017 | 6.6% |
| NEUROCRINE BIOSCIENCES INC | 5 | Q2 2017 | 9.1% |
| IRONWOOD PHARMACEUTICALS INC | 5 | Q2 2017 | 7.1% |
View BLUE JAY CAPITAL MANAGEMENT, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2017-08-11 |
| 13F-HR | 2017-05-12 |
| 13F-HR | 2017-02-13 |
| 13F-HR | 2016-11-10 |
| 13F-HR | 2016-08-12 |
| 13F-HR | 2016-05-13 |
| 13F-HR | 2016-02-12 |
| 13F-HR | 2015-11-13 |
| 13F-HR | 2015-08-13 |
| 13F-HR | 2015-05-13 |
View BLUE JAY CAPITAL MANAGEMENT, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.